October 07, 2022
2 min watch
Save
VIDEO: Drug developer targets neurotransmission to improve symptoms in AD
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
SAN DIEGO – AmyriAD Therapeutics is focusing on the upregulation of neurotransmission to improve cognition and global function in patients with Alzheimer’s disease, according to CEO Sharon L. Rogers, PhD.
“Global function is one of the key drivers both economically and in general patient quality of life in Alzheimer’s disease,” Rogers said at the Alzheimer’s Association International Conference. “The longer we can keep patients home, the better it’s going to be for everyone and the happier everyone is.”
AmyriAD is working on several small molecules, she said, with AD 101 ready for advancement into phase 3 trials in early 2023.